Bicara Therapeutics (BCAX) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bicara Therapeutics (BCAX) has outperformed Taysha Gene Therapies (TSHA) over the past year, losing 4.1% versus a loss of 12.5%. Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $1.14 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | TSHA |
|---|---|---|
| Share price | $17.26 | $4.43 |
| Market cap | $1.14B | $1.44B |
| 1-day change | +5.12% | 0.00% |
| YTD return | +2.55% | -19.45% |
| 1-year return | -4.11% | -12.45% |
| 5-year return | — | -75.22% |
| EPS (TTM) | $-3.08 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.77M |
| Revenue growth (YoY) | — | +17.28% |
| Net income (latest FY) | — | $-109.00M |
| Operating margin | — | -1130.65% |
| Net margin | — | -1115.27% |
| 52-week high | $30.99 | $7.30 |
| 52-week low | $13.70 | $3.69 |
| Distance from 52-week high | -44.30% | -39.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +105.68% | +193.45% |
| Average volume | 623.17K | 3.28M |
| Shares outstanding | 66.17M | 325.83M |
| Employees | 103 | 99 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Healthcare · Biotechnology · 103 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
BCAX vs TSHA FAQ
Which is bigger, Bicara Therapeutics or Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $1.14B for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or TSHA?
BCAX returned -4.11% over the past 12 months, compared with -12.45% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.